Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 48

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 48
---
 continued base salary and (ii) subject to his timely election of COBRA continuation coverage, coverage of all of the COBRA premiums for a period of 12 months, or until he becomes eligible to receive any health benefits through a new or through a spouse’s employer, provided that he executes an effective release of claims. Dr. Pastagia . Pursuant to the separation and release agreement entered into on December 2, 2024 between the Company and Dr. Pastagia, subject to her continued compliance with the terms thereof, Dr. Pastagia will receive salary continuation payments of her at-the-time current annual base salary of $475,072 for a period of 12 months following her termination in accordance with the regular payroll practices of the Company. 31

Mr. Rychlik . Pursuant to the separation and release agreement entered into on September 30, 2024 between the Company and Mr. Rychlik, Mr. Rychlik received (i) salary continuation payments of his at-the-time current annual base salary of $301,600 for a period of three months (equal to $75,400 in the aggregate) and (ii) subject to his timely election of COBRA continuation coverage, continued coverage of the same portion of premiums covered for all other employees of the Company of the COBRA premiums for Mr. Rychlik and his covered dependents for a period of three months following his termination, or, earlier if he becomes eligible to receive any health benefits through a new or through a spouse’s employer. Such severance benefits were contingent upon Mr. Rychlik’s continued compliance with the terms of his separation and release agreement. All of the named executive officers held stock options under our equity incentive plans that were granted subject to the general terms of our equity incentive plans and form of stock option agreements. The specific vesting terms of each of the named executive officer’s stock options are described below under “Outstanding Equity Awards at Fiscal Year End.” Other than with respect to Dr. Birx, if within one month prior to, or within 12 months after, a change in control, the named executive officer is terminated due to an involuntary termination (other than on account of death or disability), then any unvested stock options held by that officer will vest in full. Outstanding Equity Awards at Fiscal Year End The following table sets forth certain information regarding all outstanding equity awards held by the named executive officers as of December 31, 2024.

| ​                      | ​ | ​